Posted on

Nova Mentis to be Listed in the First-Ever Psychedelic Index

January 25, 2021 6:00 am Published by 

Novamentis

Vancouver, British Columbia – January 25, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has been included in the world’s first North American Psychedelic Index. Based on this index, The Horizon Psychedelic Stock Index ETF is expected to commence trading Jan. 27, 2021 under ticker “PSYK” on the NEO Exchange.

“NOVA is developing psilocybin and mushroom-based tryptamine derivatives for the treatment of autism spectrum disorder (ASD), an unmet medical need. We have started a preclinical study in a rat model of ASD and are planning to begin psilocybin treatment of the animals in February 2021. Submission of an IND to regulatory authorities and Phase 1 human safety studies are planned for later this year,” said Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board.

“We are making important progress as we bring psychedelic research into the 21st century using current medical advancements in diagnosis, treatment, and development of objective biomarkers to confirm therapeutic responses,” he continued.

The North American Psychedelic Stock Index is provided by German-based index provider Solactive @ www.solactive.com

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian based biotechnology company that is focused on the emerging field of psychedelic medicine. The Company aims to become a global leader in this field by integrating the latest state-of-the-art medical and scientific technology into its drug development program. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as Autism Spectrum Disorder (ASD).

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

CHAMPIGNON BRANDS’ CANADIAN RAPID TREATMENT CENTER OF EXCELLENCE OPENS FIRST COMMUNITY-BASED CENTRE IN OTTAWA TO PROVIDE KETAMINE TREATMENT FOR ADULTS WITH DEPRESSION

Third CRTCE Clinic effectively addresses the unmet need of depression and suicide

VANCOUVER, BRITISH COLUMBIA – Monday, January 25, 2021 – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment.

“Over twenty clinical trials have demonstrated that ketamine and esketamine have rapid and robust antidepressant effects in patients that have failed to respond to conventional antidepressants. During the COVID-19 pandemic, the need for effective treatment has become exponentially critical,” said Dr. Joshua Rosenblat, Medical Director, CRTCE. “Ketamine treatment for depression is very difficult to access in Canada. This third clinic should allow more people to access treatment.”

The first of its kind in Canada, the CRTCE multidisciplinary outpatient clinical research facility has specialized in providing breakthrough rapid onset treatments for depression, including but not limited to intravenous ketamine and intranasal esketamine. These therapies aid patients suffering from several treatment-resistant conditions such as major depressive disorder and/or bipolar disorder.

“In just 30 months through the two current CRTCE Clinics we have administered more than 2500 Intravenous Ketamine Infusions and over 60 Intranasal Ketamine treatments. Many of these patients have experienced substantial relief for what often can be debilitating depression and suicidal thinking,” said Kevin Kratiuk, Vice President of Operations, CRTCE.

To obtain treatment, patients must be referred to one of the CRTCE Clinics by family physicians, psychiatrists, or nurse practitioners. Patients with PTSD and OCD are considered on a case-by-case basis. Kratiuk continued, “This newest clinic will expand our capacity to help more people affected by depression”.

The new Ottawa clinic is in Ottawa’s Alta Vista neighbourhood. “The opening of our first Ottawa CRTCE Clinic provides an opportunity for CRTCE to provide access to new treatments for people who are suffering from depression. In addition to providing clinical care, all CRTCE Clinics conduct research that aims to improve the quality of people’s lives affected by these common and debilitating disorders in Canada,” said Dr. Roger McIntyre, CEO Champignon Brands Inc., Professor of Psychiatry and Pharmacology University of Toronto.

Background

Founded in July 2018, Canadian Rapid Treatment Center of Excellence (CRTCE) (https://www.crtce.com/) is an all-Canadian company. It operates clinics in Mississauga and Toronto and now in Ottawa.

CRTCE provides a platform for treatment development identification of and implementation breakthrough derivatives of ketamine and psychedelics, and innovative delivery platforms for the purpose of treating medical disorders like depression, post-traumatic stress disorder (PTSD) as well as substance and alcohol use disorder.

The CRTCE Clinics offer Intravenous Ketamine Infusion Therapy, Intranasal EsKetamine Therapy and Sublingual/ Oral Ketamine Therapy – all aimed at aiding those suffering from several treatment-resistant conditions. The clinic provides a comfortable environment focused on the safety and success of each individual patient.

Champignon Brands Inc. (https://braxiascientific.com) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. (“AltMed”). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.

ON BEHALF OF THE BOARD

“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO

FOR FURTHER INFORMATION PLEASE CONTACT: Champignon Brands Inc.  (416) 762-2138
Email: info@braxiascientific.com Website: www.champignonbrands.com

Media: Victoria Ollers, vollers@rogers.com, 416 822-2288

Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider. 

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company’s limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company’s industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws; failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; and failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.

Posted on

Awakn Appoints James Collins, ex-Accenture Strategy MD, as Chief Operating Officer

Today Awakn announces the appointment of James Collins as Chief Operating Officer, effective January 2021.

Collins joins from Accenture Strategy where he was a Managing Director (London) for several years, responsible for client relationship development, sales, delivery, and European & Global practise management. He is an industry thought leader with several publications on digital innovation and the transformation of industries, including major studies in collaboration with the World Economic Forum.

He will be responsible for executing corporate strategy and refining the operating model of the business. Whilst at Accenture, James was a champion for Inclusion, Diversity & Mental Health driving awareness and structural change to address inequality in the workplace. James holds a BSc and MPhil in Psychology from University College London (UCL).

“This is the perfect time to join Awakn as it begins to realise its potential to reshape the landscape in addiction and mental health treatment,” said Collins.

“The application of psychedelic medicine in the treatment of addictions and other mental health issues has the potential to transform the lives of millions of people struggling with mental health disorders, and addictions.”

Anthony Tennyson, Awakn CEO, said, “We are delighted to welcome James to Awakn. He is passionate about changing the paradigm of how addiction and mental health conditions are treated in the UK, EU, and US. This passion in addition to his experience and expertise will help us as we build and scale our business.”

Posted on

A world-renowned addictions specialist claims that psychedelics have “potential to be the equivalent of a cure for cancer in the mental health space”

Documentary explores use of psychedelic drugs for mental health issues

In a new documentary, VeraCity: The Psychedelic Frontier, a world-renowned addictions specialist claimed that psychedelics have “potential to be the equivalent of a cure for cancer in the mental health space”. The documentary explores Canada’s leading research on psilocybin and follows a Toronto war hero’s journey to heal his mind from PTSD using a psychedelic plant called Iboga.

PDF of article

Posted on

Novamind to Present at Inaugural KCSA Psychedelics Investor Conference

Features virtual presentations by eminent psychedelics companies and industry leaders

TORONTO, ON / ACCESSWIRE / January 25, 2021 / Novamind Inc. (CSE:NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, today announced the Company’s participation at the Psychedelics Investor Conference, hosted by KCSA Strategic Communications on Tuesday, January 26th and Wednesday, January 27th from 9:00 AM – 12:30 PM EST.

The two-day event will feature presentations by eminent psychedelics companies and industry leaders. Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST.

“We look forward to connecting with industry leaders and investors to discuss Novamind’s operating model for clinical care and clinical research in psychedelic medicine,” said Conforti.

Novamind recently became the latest psychedelics company to go public. On January 5th, 2021, the Company began trading on the Canadian Securities Exchange under the ticker symbol “NM”.

KCSA Strategic Communications, an integrated strategic communications firm specializing in public relations, investor relations and social media, is organizing the inaugural conference to bring together leaders and investors in the psychedelics industry.

Webcast Information
To attend the live video webcast, please register or email KCSA Strategic Communications at conference@kcsa.com.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, shareholder communications and social media, with expertise in financial and professional services, technology, healthcare, digital media, cannabis and energy. Since 1969, the Firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The Firm’s clients are its best references. For more information, please visit www.kcsa.com.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

A BC man no longer experiences panic attacks or other PTSD symptoms after microdosing psilocybin for 8 months

One man’s experience with magic mushrooms

A BC man claims that microdosing psilocybin for 8 months has eased his PTSD symptoms tremendously. The man states that he no longer experiences panic attacks and believes that psilocybin represents “freedom from being stuck in a dark place in your head”. The documentary VeraCity: The Psychedelic Frontier dives deeper into his journey through PTSD.

Posted on

Core One Labs Announces Vocan Assembles Equipment to produce biosynthesized Psilocybin

Vancouver, British Columbia, Canada – January 23, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has assembled the necessary equipment, which will allow the laboratory to commence the process of recombinant production of psilocybin.  The process that engineers bacteria incorporating optimized biosynthetic genes from the Psilocybe cubensis mushroom, will enable the bacteria to act as a biological factory and synthesize psilocybin that is cost effective using simple building blocks.

Vocan’s platform can make the active compounds that occur naturally, by using a gene mimicry process and simple chemical modifications to enable the creation of bioidentical compounds as well as known and novel analogs.  The analog compounds could prove to be more effective, targeted and safer.

Vocan has now received and assembled equipment required to move forward on its plan to produce biosynthesized psilocybin. Due to the cost and long lead times, this is a critical milestone in the company’s plan. The equipment enables Vocan to improve on the current work being conducted in the lab and puts Vocan ahead of schedule on its plan to begin the recombinant production of psilocybin.

“Vocan’s recombinant production of psilocybin is a significant improvement over the current methods of psilocybin production. Reducing both the cost and time needed to produce and purify psilocybin to only a few days, compared to much longer and more expensive methods for whole mushroom extraction. Having the equipment purchased and assembled positions Vocan to execute on its objectives in the short term.” Stated Joel Shacker CEO of the Company.

Further to the Company’s press release dated January 15, 2021 announcing the closing of its sale of non-core assets, the Company wishes to correct that it has issued a total of 500,000 common shares as an administrative fee to three arms-length third-parties who assisted with facilitating such sale, not 350,000 shares to two parties, as previously announced.

About Core One Labs Inc.

Core One Labs Inc. is a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy.  The Company has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on biosynthesized psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

 

Cautionary Disclaimer Statement:

 

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

 

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription. Health Canada has not approved psilocybin as a drug for any indication. Core One Labs Inc. does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One Labs Inc. believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One Labs Inc. does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Mydecine Innovations Group Included in First-Ever Psychedelics ETF

Published at globenewswire.com

‍

DENVER, Jan. 22, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF).

The Horizons Psychedelic Stock Index ETF index, which was announced in December 2020 and includes 17 companies in the U.S. and Canada, is expected to start trading on Tuesday, January 26 under the ticker PSYK on the NEO exchange.

“While medicinal psychedelics are certainly not new, the legal market and the ability to invest in these cutting-edge companies certainly is new,” said Joshua Bartch, Co-Founder & CEO, Mydecine. “Together, with these 17 companies, Mydecine is helping to build an industry that is investing in and researching innovative solutions for treating previously untreatable mental illness. We are honored that we are included, and we are also mindful that this now gives more people, who may be new to the space, the ability to access and diversify their investments. By having exposure to many different companies with solid fundamentals, but different approaches, philosophies, indications, and technologies, is healthy for investors in the industry.”

The ETF will will track an underlying index – the North American Psychedelic Stock Index – provided by the German-based Solactive. Additional details on the ETF, including how it is weighted and conditioned, can be found here.

Additionally, the Company will be participating in the KCSA Virtual Psychedelics Investor Conference, at 10:20 AM ET on Wednesday January 27, 2021.

About Mydecine Innovations Group
Mydecine Innovations Group™ (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

‍

Posted on

HAVN LIFE SCIENCES ANNOUNCES INCLUSION IN FIRST PSYCHEDELIC EXCHANGE TRADED FUND

Havn Life is one of a select number of companies that are included in the new ETF

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the first psychedelics Exchange Traded Fund (“ETF”)  (NEO: PSYK). The ETF will begin trading on the Neo Exchange on January 26, 2021.

The ETF will invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances.

Havn Life is one of seventeen companies that met the requirements of listing within the ETF. The ETF is managed by Horizons ETF Management, one the largest ETF providers in Canada, with over CDN $16 billion in assets under management across 93 ETFs. Horizons also  brought the first cannabis ETF to market in 2017 and continues to lead the industry with ETFs in emerging industries. Inclusion into an ETF is an important milestone for Havn Life’s investors and stakeholders. The ETF will bring additional exposure to potential new investors and generate value for existing shareholders.

Tim Moore remarked, “Our team is excited to be included in Horizons Psychedelics ETF, which will allow Havn Life to become visible to and available to a wider investment community. This is an opportunity to provide added shareholder value as we continue to execute our operational milestones.”

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram and Youtube.

Connect

Investor Relations
ir@havnlife.com
(604) 687-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life
Youtube: @HavnLife

Media Contact
savi@emergence-creative.com
(647) 896-8078

 

LinkedInFacebookTwitterEmailShare